Loading asset research
Alumis Inc. Common Stock
ALMSNasdaq · USD · StocksQuote as of · Exchange session not verified$9.17
-7.37%
Today
ALMS
Loading 1D prices…
Market cap
$1.2B
Volume
3.4M
52w high
$31.3552w low
$3.76Company profile
Alumis Inc. Common Stock
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
Sector
Health Care
Industry
Pharmaceutical Preparations
Exchange
Nasdaq
Display currency
USD
Location
South San Francisco, CA, United States
Employees
237
Fiscal year end
1231
CIK
1847367
Session & valuation
Open$9.99
Previous close$9.90
Day high$10.10
Day low$9.14
30-day avg. volume2.8M
Outstanding shares—
Diluted EPS-$2.86
Latest annual period
P/E (trailing)-3.21
P/E (forward)-3.19
Price / book2.61
Beta-0.79
Dividend yield—
Deterministic peer set
Companies with SEC SIC 2834
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| OPKOPKO Health Inc. Common Stock | $1.2B | $606.9M | -37186.98% | -$0.30 | +5.37% | Buy |
| MNKDMannKind Corporation Common Stock | $1.2B | $349M | +1.68% | $0.02 | -0.79% | Buy |
| JBIOJade Biosciences Inc. Common Stock | $1.1B | $0.00 | — | -$3.19 | -6.84% | Buy |
| ORICOric Pharmaceuticals Inc. Common Stock | $1.2B | $0.00 | — | -$1.47 | -0.29% | Buy |
| SPTXSeaport Therapeutics Inc. Common Stock | $1.2B | $0.00 | — | -$1.94 | +0.26% | Buy |